Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.48 |
| ▸ | KDM5C | P41229 | 5/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | KDM6B | O15054 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144982 | 0.79 | KDM4C (0.47) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL17144777 | 0.77 | KDM4C (0.58) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL19741663 | 0.75 | KDM4C (0.56) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL17144722 | 0.75 | KDM4C (0.56) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL15636461 | 0.69 | KDM4C (0.76) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL2305288 | 0.69 | KDM4C (0.76) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL16291774 | 0.68 | KDM4C (0.74) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL17144210 | 0.68 | KDM4C (0.59) | KDM4CKDM5CKDM2BKDM5BKDM5A | |
| SCHEMBL19741628 | 0.68 | KDM5C (0.61) | KDM4CKDM5CL3MBTL1KDM4E | |
| SCHEMBL21257809 | 0.67 | KDM4C (0.51) | KDM4CKDM5CKDM2BKDM5BKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | claimed |
| EP-3126345-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153498-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS, APS (DK) | 2015-10-08 | — | — | WO | claimed |
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM3A, KDM1A | KDM4C 38/4885KDM5C 16/4885KDM2B 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.